News & Updates
Showing Obstetrics & Gynaecology articles
Showing
Show Multimedia Only
ICON8B OS data support a new SoC for epithelial ovarian cancer
29 Oct 2025
byAudrey Abella
In the final overall survival (OS) analysis of the phase III ICON8B trial, first-line treatment with bevacizumab in combination with a chemotherapeutic regimen comprising carboplatin Q3W and dose-dense paclitaxel QW improved survival in women with high-risk stage III-IV epithelial ovarian cancer.








